Trial reportDrug and alcohol dependence2019
A community pharmacy-led intervention for opioid medication misuse: A small-scale randomized clinical trial.
Trial report in Drug and alcohol dependence, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Combatting opioid misuse, overuse and abuse: a systematic review of pharmacists' services and outcomes.Pain management · 2024Pooled it
- Co-use of Opioid Medications and Alcohol Prevention Study (COAPS).Substance abuse · 2023Trial
- A Systematic Review of Pharmacists Using Motivational Interviewing and Patient Outcomes.Pharmacy (Basel, Switzerland) · 2026Review
- A short communication of pain outcomes following a pharmacist-delivered alcohol and opioid use reduction intervention.Drug and alcohol dependence reports · 2026Article
- Exploratory analysis of pharmacist involvement in motivational interviewing intervention for patients with prescription opioid misuse behaviors.JAPhA practice innovations · 2026Article
- Barriers and facilitators to the implementation of screening and intervention for co-use of opioid medications and alcohol among community pharmacy patients.Journal of substance use and addiction treatment · 2025Article
- CTN-0138: adaptation, implementation, and cluster randomized trial of a Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool-a protocol paper.Addiction science & clinical practice · 2024Article
- Patient and pharmacist perspectives on opioid misuse screening and brief interventions in community pharmacies.Addiction science & clinical practice · 2024Article
- Engaging community pharmacies in practice-based research: Lessons from opioid-focused research.Research in social & administrative pharmacy : RSAP · 2024Article
- A Social History of Opioids' Crimedical Cycle.Addiction research & theory · 2024Article
- Organizational Readiness to Implement Community Pharmacy-Based Opioid Counseling and Naloxone Services: A Scoping Review of Current Practice Models and Opportunities.Pharmacy (Basel, Switzerland) · 2023Article
- Addressing the Opioid Crisis-The Need for a Pain Management Intervention in Community Pharmacies in Canada: A Narrative Review.Pharmacy (Basel, Switzerland) · 2023Review
- High opioid doses, naloxone, and central nervous system active medications received by Medicare-enrolled adults.Journal of the American Geriatrics Society · 2023Article
- Addressing opioid medication misuse at point of service in community pharmacy: A study protocol for an interdisciplinary behavioral health trial.Contemporary clinical trials · 2022Article
- Risky alcohol use among patients dispensed opioid medications: A clinical community pharmacy study.Drug and alcohol dependence · 2022Article
- Validation of the tobacco, alcohol, prescription medication, and other substance use (TAPS) tool with the WHO alcohol, smoking, and substance Involvement screening test (ASSIST).Addictive behaviors · 2022Article
- Brief intervention medication therapy management: Establishment of an opioid misuse intervention model delivered in a community pharmacy.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2021Article
- Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.Substance abuse · 2020Article
- Screening tools for detecting problematic opioid use and potential application to community pharmacy practice: a review.Integrated pharmacy research & practice · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundStemming the opioid epidemic requires testing novel interventions. Toward this goal, feasibility and acceptability of a Brief Motivational Intervention-Medication Therapy Management (BMI-MTM) intervention was examined along with its impact on medication misuse and concomitant health conditions.
methodsWe conducted a two-group randomized trial in 2 community pharmacies. We screened patients for prescription opioid misuse at point-of-service using the Prescription Opioid Misuse Index. Participants were assigned to standard medication counseling (SMC) or SMC + BMI-MTM (referred to as BMI-MTM herein). BMI-MTM consists of a pharmacist-led medication counseling/brief motivational session and 8-weekly patient navigation sessions. Assessments were at baseline, 2-, and 3-months. Primary outcomes included feasibility, acceptability, and mitigation of opioid medication misuse. Secondary outcomes included pain and depression. Outcomes were analyzed with descriptive and multivariable statistics (intent-to-treat [ITT] and adjusted for number of sessions completed [NUMSESS]).
resultsThirty-two participants provided informed consent (74.4% consent rate; SMC n = 17, BMI-MTM n = 15; 3-month assessment retention ≥93%). Feasibility was demonstrated by all BMI-MTM recipients completing the pharmacist session and an average of 7 navigation sessions. BMI-MTM recipients indicated ≥4.2 (5 maximum) level of satisfaction with the pharmacist-led session, and 92.4% were satisfied with navigation sessions. Compared to SMC at 3-months, BMI-MTM recipients reported greater improvements in misuse (ITT: Adjusted Odds Ratio [AOR] = 0.13; 95% CI = 0.05, 0.35, p < 0.001. NUMSESS: AOR = 0.05; 95% CI = 0.01, 0.25; p < 0.001), pain (ITT: В = 8.8, 95% CI=-0.95, 18.5, p = 0.08; NUMSESS: В = 14.0, 95% CI = 3.28, 24.8, p = 0.01), and depression (ITT: B= -0.44; 95% CI=-0.65, -0.22; p < 0.001. NUMSESS: B= -0.64; 95% CI=-0.82, -0.46; p < 0.001).
conclusionsBMI-MTM is a feasible misuse intervention associated with superior satisfaction and outcomes than SMC. Future research should test BMI-MTM in a large-scale, fully-powered trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.